Molecular chemotherapy and chemotherapy: A new front against late-stage hormone-refractory prostate cancer

Clinical Cancer Research

Volumn 17, Issue 12, 2011, Pages 4006-4018

  Singh, Preetiner Pal ^a,c,f   Joshi, Swapna ^b   Russell, Pamela J ^d,e   Verma, Nirupama D ^a,c   Wang, Xiaochun ^a,c   Khatri, Aparajita ^a,c  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b Lowy Cancer Research Centre   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d Translational Research Institute   (Australia)

^e QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^f MONASH MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; CREATININE; DOCETAXEL; FLUDARABINE PHOSPHATE; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PURINE NUCLEOSIDE PHOSPHORYLASE; UREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CELL ASSAY; CELL INFILTRATION; CELL KILLING; CELL VIABILITY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; GENE DIRECTED ENZYME PRODRUG THERAPY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN VITRO STUDY; LETHARGY; LIVER TOXICITY; LUNG METASTASIS; MALE; MOLECULAR THERAPY; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; TH2 CELL; TREATMENT OUTCOME; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM; WEIGHT REDUCTION;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM STAGING; PROSTATIC NEOPLASMS; PURINE-NUCLEOSIDE PHOSPHORYLASE; TAXOIDS; TH2 CELLS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79959222723     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0248     Document Type: Article

References (50)

1. Lin AM, Small EJ. Prostate cancer update: 2007. Curr Opin Oncol 2008;20:294-9.
2. Lin DW, Porter M, Montgomery B. Treatment and survival outcomes in young men diagnosed with prostate cancer: a population-based cohort study. Cancer 2009;115:2863-71.
3. So A, Gleave M, Hurtado-Col A, Nelson C. Mechanisms of the development of androgen independence in prostate cancer. 2005;23:1-9.
4. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs 1998;9:1-17. (Pubitemid 28088174)
5. Petrylak DP. The treatment of hormone-refractory prostate cancer: docetaxel and beyond. Rev Urol 2006;8 Suppl2:S48-55.
6. Singh P, Yam M, Russell PJ, Khatri A. Molecular and traditional chemotherapy: a united front against prostate cancer. Cancer Lett 2010;293:1-14.
7. Anderson J, Van Poppel H, Bellmunt J, Miller K, Droz JP, Fitzpatrick JM. Chemotherapy for older patients with prostate cancer. BJU Int 2007;99:269-73. (Pubitemid 46103102)
8. Parker WB, Allan PW, Shaddix SC, Rose LM, Speegle HF, Gillespie GY, et al. Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem Pharmacol 1998;55:1673-81. (Pubitemid 28223460)
9. Wang XY, Martiniello-Wilks R, Shaw JM, Ho T, Coulston N, Cooke-Yarborough C, et al. Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivery by ovine atadenovirus. Gene Ther 2004;11:1559-67. (Pubitemid 39433476)
10. Martiniello-Wilks R, Tsatralis T, Russell PJ, Brookes DE, Zandvliet D, Lockett LJ, et al. Transcription-targeted gene therapy for androgen-independent prostate cancer. Cancer Gene Ther 2002;9:443-52.
11. Martiniello-Wilks R, Wang XY, Voeks DJ, Dane A, Shaw JM, Mortensen E, et al. Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer. J Gene Med 2004;6:1343-57. (Pubitemid 40287706)
12. Martiniello-Wilks R, Dane A, Voeks DJ, Jeyakumar G, Mortensen E, Shaw JM, et al. Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease. J Gene Med 2004;6:43-54. (Pubitemid 40228002)
13. McLaughlin P, Robertson LE, Keating MJ. Fludarabine phosphate in lymphoma: an important new therapeutic agent. Cancer Treat Res 1996;85:3-14.
14. Endo S, Sato Y, Hasegawa T, Tetsuka K, Otani S, Saito N, et al. Preoperative chemotherapy increases cytokine production after lung cancer surgery. Eur J Cardiothorac Surg 2004;26:787-91. (Pubitemid 39273581)
15. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004;202:275-93. (Pubitemid 39576919)
16. Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother 2004;58:24-38. (Pubitemid 38117046)
17. Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 2008;8:887-99.
18. Khatri A, Husaini Y, Ow K, Chapman J, Russell PJ. Cytosine deaminase-uracil phosphoribosyltransferase and interleukin (IL)-12 and IL- 18: a multimodal anticancer interface marked by specific modulation in serum cytokines. Clin Cancer Res 2009;15:2323-34.
19. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1996;22:27-55.
20. Khatri A, Zhang B, Doherty E, Chapman J, Ow K, Pwint H, et al. Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in mice. J Gene Med 2006;8:1086-96. (Pubitemid 44480401)
21. Voeks DJ, Martiniello-Wilks R, Russell PJ. Derivation of MPR and TRAMP models of prostate cancer and prostate cancer metastasis for evaluation of therapeutic strategies. Urol Oncol 2002;7:111-8.
22. Khatri A, Husaini Y, Ow K, Chapman J, Russell PJ. Cytosine deaminase-uracil phosphoribosyltransferase and interleukin (IL)-12 and IL-18: a multimodal anticancer interface marked by specific modulation in serum cytokines. Clin Cancer Res 2009;15:2323-34.
23. Thompson TC, Southgate J, Kitchener G L. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 1989;56:917-30. (Pubitemid 19091004)
24. Grant JF, Iwasawa T, Sinn HW, Siemens DR, Griffith TS, Takacs EB, et al. Induction of protective immunity to RM-1 prostate cancer cells with ALVAC-IL-2/IL-12/TNF-alpha combination therapy. Int J Cancer 2006;119:2632-41. (Pubitemid 44691319)
25. Martiniello-Wilks R, Garcia-Aragon J, Daja MM, Russell P, Both GW, Molloy PL, et al. In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Hum Gene Ther 1998;9:1617-26.
26. Seki M, Iwakawa J, Cheng H, Cheng PW. P53 and PTEN/MMAC1/TEP1 gene therapy of human prostate PC-3 carcinoma xenograft, using transferrin- facilitated lipofection gene delivery strategy. Hum Gene Ther 2002;13:761-73. (Pubitemid 34280489)
27. Chun JY, Nadiminty N, Dutt S, Lou W, Yang JC, Kung HJ, et al. Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res 200915:4815-22.
28. Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, et al. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res 2007;67:9417-24. (Pubitemid 47535932)
29. Lu Y, Cai Z, Xiao G, Keller ET, Mizokami A, Yao Z, et al. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Res 2007;67:3646-53. (Pubitemid 46762149)
30. Lu Y, Chen Q, Corey E, Xie W, Fan J, Mizokami A, et al. Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone. Clin Exp Metastasis 2009;26:161-9.
31. Malinowska K, Neuwirt H, Cavarretta IT, Bektic J, Steiner H, Dietrich H, et al. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer 2009;16:155-69.
32. Mimeault M, Batra SK. Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J Cell Physiol 2010;224:626-35.
33. Wegiel B, Bjartell A, Culig Z, Persson JL. Interleukin-6 activates PI3K/ Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. Int J Cancer 2008;122:1521-9. (Pubitemid 351294960)
34. Zhang L, Sun SK, Shi LX, Zhang X. [Serum cytokine profiling of prostate cancer and benign prostatic hyperplasia using recombinant antibody microarray]. Zhonghua Nan Ke Xue 2010;16:584-8.
35. Li Y, Okegawa T, Lombardi DP, Frenkel EP, Hsieh JT. Enhanced transgene expression in androgen independent prostate cancer gene therapy by taxane chemotherapeutic agents. J Urol 2002;167:339-46. (Pubitemid 34024582)
36. Yu DC, Chen Y, Dilley J, Li Y, Embry M, Zhang H, et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 2001;61:517-25. (Pubitemid 32128610)
37. Lockett LJ, Molloy PL, Russell PJ, Both GW. Relative efficiency of tumour cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors. Clin Cancer Res 1997;3:2075-80. (Pubitemid 27505135)
38. Gonzalez H, Leblond V, Azar N, Sutton L, Gabarre J, Binet JL, et al. Severe autoimmune hemolytic anemia in eight patients treated with fludarabine. Hematol Cell Ther 1998;40:113-8. (Pubitemid 28280560)
39. Voeks D, Martiniello-Wilks R, Madden V, Smith K, Bennetts E, Both GW, et al. Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models. Gene Ther 2002;9:759-68. (Pubitemid 34679303)
40. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750-7.
41. Snyder FF, Lukey T. Kinetic considerations for the regulation of adenosine and deoxyadenosine metabolism in mouse and human tissues based on a thymocyte model. Biochim Biophys Acta 1982;696:299-307. (Pubitemid 12106188)
42. Van Tellingen O, Beijnen JH, Verweij J, Scherrenburg EJ, Nooijen WJ, Sparreboom A. Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. Clin Cancer Res 1999;5:2918-24. (Pubitemid 29493971)
43. Legrier ME, Oudard S, Judde JG, Guyader C, de Pinieux G, Boye K, et al. Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms. Br J Cancer 2007;96:269-76. (Pubitemid 46160632)
44. Agarwal A, Agrawal U, Verma S, Mohanty NK, Saxena S. Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy. Immunopharmacol Immunotoxicol 2010;32:348-56.
45. Cui G, Florholmen J. Polarization of cytokine profile from Th1 into Th2 along colorectal adenoma-carcinoma sequence: implications for the biotherapeutic target? Inflamm Allergy Drug Targets 2008;7:94-7.
46. Lee SO, Pinder E, Chun JY, Lou W, Sun M, Gao AC. Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells. Prostate 2008;68:85-91.
47. Cardillo MR, Ippoliti F. IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis. Anticancer Res 2006;26:3409-16.
48. Kesarwani P, Ahirwar DK, Mandhani A, Singh AN, Dalela D, Srivastava AN, et al. IL-10-1082 G>A: a risk for prostate cancer but may be protective against progression of prostate cancer in North Indian cohort. World J Urol 2009;27:389-96.
49. Wang MH, Helzlsouer KJ, Smith MW, Hoffman-Bolton JA, Clipp SL, Grinberg V, et al. Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate 2009;69:874-85.
50. Wise GJ, Marella VK, Talluri G, Shirazian D. Cytokine variations in patients with hormone-treated prostate cancer. J Urol 2000;164:722-5. (Pubitemid 30637610)